- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Aceon
Synonyms :
Class :
Antihypertensives; ACE Inhibitors
Dosage forms & Strengths:
Adult:
Tablet:
2 mg
4 mg
8 mg
4 - 8
mg
every day
or divided 2 times a day; increase up to 16 mg/day
Diuretic may be added
4
mg
Orally
every day
2
weeks
; increase up to 8 mg/day orally divided into 2 times a day
congestive Heart Failure (CHF)
2
mg
Orally every day; increase up to 8-16 mg
Not recommended for pediatrics
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
may increase the toxic effect of angiotensin receptor II blockers
may increase the toxic effect of angiotensin receptor II blockers
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with ACE inhibitors
may enhance the concentration of serum when combined with lithium
grass pollens allergen extract
may have an increasingly adverse effect when combined with grass pollen extract
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may enhance the risk of neutropenia poliovirus vaccine inactivated
choline magnesium trisalicylate
salicylates may enhance the nephrotoxic effect of ACE Inhibitors
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
Icatibant may diminish the effect of ACE Inhibitors
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may have an increasingly adverse effect when combined with alteplase
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased myelosuppressive effect when combined with azathioprine
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
polyethylene glycol and electrolytes
They may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
may increase the toxic effects of dipeptidyl peptidase-IV inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
may have an increasingly adverse effect when combined with iron dextran complex
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
>10%:
Headache
Cough
1-10%:
Dizziness
Back pain
Lower back pain
Abnormal ECG
Palpitation
Depression
Somnolence
Menstrual disorder
Edema
ALT increased
Sexual dysfunction
Sleep disorder
Chest pain
Nausea
Vomiting
Flatulence
Rash
Hyperkalemia
Tinnitus
Frequency undefined:
Intestinal angioedema
Syncope
Liver failure
Vertigo
Leukopenia
Urinary retention
Amnesia
Pruritus
Stroke
Perindopril is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
Category D
Breastfeeding warnings:
The drug excretion in breastmilk is unknown; hence use with caution
Pregnancy category:
Patient information leaflet
Generic Name: perindopril
Pronounced: per-in-dop-ril
Why do we use perindopril?
Perindopril treats hypertension and corona artery disease.
ADVERTISEMENT
